CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Blood samples collectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug212 Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB) Wiki 1.00
drug2551 Saliva collection Wiki 0.45

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Human Ab Response & immunoMONItoring of COVID-19 Patients

Prospective, mono centric study on COVID-19 patients with or without acute respiratory distress syndrome (ARDS) to analyse the dynamics of the immune response and to search for biomarkers of evolution

NCT04373200 SARS-CoV-2 Coronavirus Acute Respiratory Distress Syndrome Biological: Blood samples collection Other: Saliva collection
MeSH:Coronavirus Infections Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Description: Blood sample

Measure: Number of increased immune population

Time: Month 4

Description: Blood sample

Measure: Number of decreased immune population

Time: Month 4

Description: Blood sample

Measure: Number of statically different phenotypes compared to control patients

Time: Month 4

Secondary Outcomes

Description: Qualitative identification of immune subpopulations showing a significant variation compared to controls and quantification of this variation (at D1 and/or D14)

Measure: Gain or loss of functional phenotypic markers between D1 and D14

Time: Day 14

Description: Qualitative identification of immune subpopulations showing a significant variation between acute and mild COVID-19 and quantification of this variation (at D1 and/or D14)

Measure: Gain or loss of functional phenotypic markers between between acute and mild infections

Time: Day 14

Description: Qualitative identification of immune subpopulations showing a significant variation between acute stage and recovery (at 4 months) and quantification of this variation

Measure: Gain or loss of functional phenotypic markers between D1 and month 4

Time: Month 4

Description: Blood sample

Measure: Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19

Time: Day 14

Description: Blood sample

Measure: Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies

Time: Month 4

Description: Blood sample

Measure: Characterization of a new set of human antibodies from patients who have recovered of COVID-19

Time: Month 4

No related HPO nodes (Using clinical trials)